Gent, Oost-Vlaanderen, Belgium VIB appeared to be the Corporate Investor, which was created in 1996. The company was established in Europe in Belgium. The main department of described Corporate Investor is located in the Gent.
The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the VIB, startups are often financed by Gimv, Qbic, PMV. The meaningful sponsors for the fund in investment in the same round are Gimv, PMV, V-Bio Ventures. In the next rounds fund is usually obtained by Gimv, Sofinnova Partners, Qbic Fund.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - Belgium. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight AgroSavfe, GlobalYeast, Aphea.Bio. Among the most successful fund investment fields, there are AgTech, Industrial.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2016. This VIB works on 11 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2019. The fund is constantly included in less than 2 deals per year.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Confo Therapeutics | $70M | 26 Jul 2024 | City of Brussels, Belgium | ||
Augustine Therapeutics | $20M | 26 Jun 2024 | Ghent, East Flanders, Belgium | ||
Tanai Therapeutics | 06 Dec 2023 | Gent, Oost-Vlaanderen, Belgium | |||
Dualyx | $47M | 15 May 2023 | Ghent, Oost-Vlaanderen, Belgium | ||
Muna Therapeutics | $73M | 09 Jul 2021 | Copenhagen, Hovedstaden, Denmark | ||
Aphea.Bio | $21M | 14 Apr 2021 | Ghent, East Flanders, Belgium | ||
Aphea.Bio | $4M | 01 Apr 2021 | Ghent, East Flanders, Belgium | ||
Animab | $4M | 27 Oct 2020 | Belgium, East Flanders | ||
ExeVir Bio | $49M | 28 Jul 2020 | Ghent, East Flanders, Belgium |
– Muna Therapeutics from Copenhagen develops small molecule programs focused on repairing neuronal dysfunction, resolving neuroinflammation and restoring neuroprotection and resilience to disease.
– The company raised $73m in Series A funding.
– The round was led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB.
– The company intends to use the funds to advance its programs to IND applications.
– ExeVir from Ghent, Belgium develops single domain antibody therapies providing broad protection against viral infections.
– The company closed its Series A financing raising a total of US$50m.
– Led by Fund+, the round was also joined by VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest as well as several Belgian family offices.
– The company is using the funds to commence the global phase 1b/2 clinical trial of lead compound XVR011 and develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Confo Therapeutics | $70M | 26 Jul 2024 | City of Brussels, Belgium | ||
Augustine Therapeutics | $20M | 26 Jun 2024 | Ghent, East Flanders, Belgium | ||
Tanai Therapeutics | 06 Dec 2023 | Gent, Oost-Vlaanderen, Belgium | |||
Dualyx | $47M | 15 May 2023 | Ghent, Oost-Vlaanderen, Belgium | ||
Muna Therapeutics | $73M | 09 Jul 2021 | Copenhagen, Hovedstaden, Denmark | ||
Aphea.Bio | $21M | 14 Apr 2021 | Ghent, East Flanders, Belgium | ||
Aphea.Bio | $4M | 01 Apr 2021 | Ghent, East Flanders, Belgium | ||
Animab | $4M | 27 Oct 2020 | Belgium, East Flanders | ||
ExeVir Bio | $49M | 28 Jul 2020 | Ghent, East Flanders, Belgium |
